These findings indicate that decreased pGSK3βY216 level is probably a consequence of the GSK3β inhibitors acting against GSK3β in tumor cells in mice, although the primary mechanism of action of these inhibitors is to compete with ATP for the ATP-binding pocket in GSK3β30,34. This evidence concerns the gene GSK3B and neoplasm.